TempraMed

Company Overview

Snapshot

Founded in October 2014 by Ron Nagar and Elina Nagar, TempraMed operates with 11–50 employees. The company has raised over $10.18 million across six funding rounds and went public on the CSE in October 2025.

Business overview

TempraMed develops patent-protected technology for temperature-controlled medication storage and tracking. Its core products, such as the VIVI Cap and VIVI Epi, utilize smart thermal shields combining ultrahigh vacuum thermal insulation and phase change materials to maintain temperature stability for injectable medications like insulin and EpiPens, without external power. The company serves patients, healthcare providers, and payors globally, operating within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

TempraMed is rapidly expanding its global market reach and product portfolio, evidenced by a series of strategic distribution agreements and product launches in the first half of 2026. This includes an exclusive distribution partnership in Brazil, a non-binding LOI in Saudi Arabia, and an LOI for exclusive distribution in Kuwait, alongside the expansion of its strategic partnership with McKesson Medical-Surgical across North America. These developments signal strong commercial momentum and a concerted effort to penetrate key international markets and B2B channels, enhancing accessibility for its temperature-sensitive medication solutions.

Company Intelligence Q&A

What was a significant recent commercial expansion for TempraMed?

In June 2026, TempraMed signed an agreement for an exclusive distribution partnership in Brazil, targeting one of the largest diabetes and biologics markets globally.

How is TempraMed strengthening its North American presence?

In June 2026, TempraMed expanded its strategic partnership with McKesson Medical-Surgical to accelerate North American growth and launch its full portfolio across B2B channels.

What recent intellectual property milestone did TempraMed achieve?

In May 2026, TempraMed announced a granted Indian Design Patent for its VIVI Cap Smart Product, reinforcing its global intellectual property position.

When did TempraMed launch a new product for biologics and injectable medications?

In January 2026, TempraMed launched its new product, "VIVI Med," designed to unlock new growth opportunities in high-value biologics and injectable medications.

What strategic media partnership did TempraMed enter into in early 2026?

In February 2026, TempraMed entered a strategic media partnership with Dr. Phil's Envoy Media, aiming to validate its product portfolio and accelerate market adoption across the United States.